FY2025 EPS Estimates for Cresco Labs Lowered by Analyst

Key Points

• Alliance Global Partners has revised Cresco Labs' FY2025 earnings per share (EPS) estimate to (0.11), down from a previous forecast of (0.09), while the current consensus estimate is (0.20) EPS.
• Cresco Labs reported quarterly earnings of (0.05) EPS, missing analyst expectations by (0.01) and achieving revenues of $163.62 million, surpassing estimates.
• Canaccord Genuity Group downgraded Cresco Labs from a "strong-buy" to a "moderate buy" rating, although one analyst still rates it as a "Strong Buy" and another as "Hold."

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Alliance Global Partners cut their FY2025 earnings per share (EPS) estimates for shares of Cresco Labs in a research note issued to investors on Wednesday, August 20th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings per share of ($0.11) for the year, down from their previous estimate of ($0.09). The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Alliance Global Partners also issued estimates for Cresco Labs' FY2026 earnings at ($0.04) EPS.

Separately, Canaccord Genuity Group lowered Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a research note on Tuesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy".

Cresco Labs Stock Down 1.4%

Shares of Cresco Labs stock traded down $0.02 during trading on Friday, reaching $1.37. The stock had a trading volume of 393,587 shares, compared to its average volume of 808,102. The company has a market capitalization of $672.70 million, a price-to-earnings ratio of -10.54 and a beta of 1.42. The stock has a fifty day moving average price of $0.71 and a two-hundred day moving average price of $0.72. Cresco Labs has a 52 week low of $0.43 and a 52 week high of $1.80. The company has a current ratio of 3.10, a quick ratio of 2.22 and a debt-to-equity ratio of 1.33.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). Cresco Labs had a negative return on equity of 11.77% and a negative net margin of 6.67%.The firm had revenue of $163.62 million for the quarter, compared to the consensus estimate of $162.00 million.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.